Global epidemiology of non-influenza RNA respiratory viruses: data gaps and a growing need for surveillance

INSPIRE investigators

Research output: Contribution to journalReview article

Abstract

Together with influenza, the non-influenza RNA respiratory viruses (NIRVs), which include respiratory syncytial virus, parainfluenza viruses, coronavirus, rhinovirus, and human metapneumovirus, represent a considerable global health burden, as recognised by WHO's Battle against Respiratory Viruses initiative. By contrast with influenza viruses, little is known about the contemporaneous global diversity of these viruses, and the relevance of such for development of pharmaceutical interventions. Although far less advanced than for influenza, antiviral drugs and vaccines are in different stages of development for several of these viruses, but no interventions have been licensed. This scarcity of global genetic data represents a substantial knowledge gap and impediment to the eventual licensing of new antiviral drugs and vaccines for NIRVs. Enhanced genetic surveillance will assist and boost research and development into new antiviral drugs and vaccines for these viruses. Additionally, understanding the global diversity of respiratory viruses is also part of emerging disease preparedness, because non-human coronaviruses and paramyxoviruses have been listed as priority concerns in a recent WHO research and development blueprint initiative for emerging infectious diseases. In this Personal View, we explain further the rationale for expanding the genetic database of NIRVs and emphasise the need for greater investment in this area of research.

Original languageEnglish (US)
Pages (from-to)e320-e326
JournalThe Lancet Infectious Diseases
Volume17
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

RNA Viruses
Epidemiology
Viruses
Antiviral Agents
Coronavirus
Human Influenza
Vaccines
Research
Metapneumovirus
Emerging Communicable Diseases
Genetic Databases
Paramyxoviridae Infections
Rhinovirus
Respiratory Syncytial Viruses
Influenza Vaccines
Licensure
Orthomyxoviridae
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Global epidemiology of non-influenza RNA respiratory viruses : data gaps and a growing need for surveillance. / INSPIRE investigators.

In: The Lancet Infectious Diseases, Vol. 17, No. 10, 01.10.2017, p. e320-e326.

Research output: Contribution to journalReview article

@article{c5922b03ac964663b761e34d4c2c42b0,
title = "Global epidemiology of non-influenza RNA respiratory viruses: data gaps and a growing need for surveillance",
abstract = "Together with influenza, the non-influenza RNA respiratory viruses (NIRVs), which include respiratory syncytial virus, parainfluenza viruses, coronavirus, rhinovirus, and human metapneumovirus, represent a considerable global health burden, as recognised by WHO's Battle against Respiratory Viruses initiative. By contrast with influenza viruses, little is known about the contemporaneous global diversity of these viruses, and the relevance of such for development of pharmaceutical interventions. Although far less advanced than for influenza, antiviral drugs and vaccines are in different stages of development for several of these viruses, but no interventions have been licensed. This scarcity of global genetic data represents a substantial knowledge gap and impediment to the eventual licensing of new antiviral drugs and vaccines for NIRVs. Enhanced genetic surveillance will assist and boost research and development into new antiviral drugs and vaccines for these viruses. Additionally, understanding the global diversity of respiratory viruses is also part of emerging disease preparedness, because non-human coronaviruses and paramyxoviruses have been listed as priority concerns in a recent WHO research and development blueprint initiative for emerging infectious diseases. In this Personal View, we explain further the rationale for expanding the genetic database of NIRVs and emphasise the need for greater investment in this area of research.",
author = "{INSPIRE investigators} and Tang, {Julian W.} and Lam, {Tommy T.} and Hassan Zaraket and Lipkin, {W. Ian} and Drews, {Steven J.} and Hatchette, {Todd F.} and Heraud, {Jean Michel} and Koopmans, {Marion P.} and Abraham, {Ashta Mary} and Amal Baraket and Seweryn Bialasiewicz and Caniza, {Miguela A.} and Chan, {Paul KS} and Cheryl Cohen and Andr{\'e} Corriveau and Cowling, {Benjamin J.} and Drews, {Steven J.} and Marcela Echavarria and Ron Fouchier and Fraaij, {Pieter LA} and Hachette, {Todd F.} and Heraud, {Jean Michel} and Hamid Jalal and Lance Jennings and Alice Kabanda and Kadjo, {Herve A.} and Khanani, {Mohammed Rafiq} and Koay, {Evelyn SC} and Koopmans, {Marion P.} and Mel Krajden and Lam, {Tommy T.} and Lee, {Hong Kai} and Lipkin, {W. Ian} and Julius Lutwama and David Marchant and Hidekazu Nishimura and Pagbajabyn Nymadawa and Pinsky, {Benjamin A.} and Sanjiv Rughooputh and Joseph Rukelibuga and Taslimarif Saiyed and Anita Shet and Theo Sloots and Tamfum, {JJ Muyembe} and Tang, {Julian W.} and Stefano Tempia and Sarah Tozer and Florette Treurnicht and Matti Waris and Aripuana Watanabe",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/S1473-3099(17)30238-4",
language = "English (US)",
volume = "17",
pages = "e320--e326",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "Lancet Publishing Group",
number = "10",

}

TY - JOUR

T1 - Global epidemiology of non-influenza RNA respiratory viruses

T2 - data gaps and a growing need for surveillance

AU - INSPIRE investigators

AU - Tang, Julian W.

AU - Lam, Tommy T.

AU - Zaraket, Hassan

AU - Lipkin, W. Ian

AU - Drews, Steven J.

AU - Hatchette, Todd F.

AU - Heraud, Jean Michel

AU - Koopmans, Marion P.

AU - Abraham, Ashta Mary

AU - Baraket, Amal

AU - Bialasiewicz, Seweryn

AU - Caniza, Miguela A.

AU - Chan, Paul KS

AU - Cohen, Cheryl

AU - Corriveau, André

AU - Cowling, Benjamin J.

AU - Drews, Steven J.

AU - Echavarria, Marcela

AU - Fouchier, Ron

AU - Fraaij, Pieter LA

AU - Hachette, Todd F.

AU - Heraud, Jean Michel

AU - Jalal, Hamid

AU - Jennings, Lance

AU - Kabanda, Alice

AU - Kadjo, Herve A.

AU - Khanani, Mohammed Rafiq

AU - Koay, Evelyn SC

AU - Koopmans, Marion P.

AU - Krajden, Mel

AU - Lam, Tommy T.

AU - Lee, Hong Kai

AU - Lipkin, W. Ian

AU - Lutwama, Julius

AU - Marchant, David

AU - Nishimura, Hidekazu

AU - Nymadawa, Pagbajabyn

AU - Pinsky, Benjamin A.

AU - Rughooputh, Sanjiv

AU - Rukelibuga, Joseph

AU - Saiyed, Taslimarif

AU - Shet, Anita

AU - Sloots, Theo

AU - Tamfum, JJ Muyembe

AU - Tang, Julian W.

AU - Tempia, Stefano

AU - Tozer, Sarah

AU - Treurnicht, Florette

AU - Waris, Matti

AU - Watanabe, Aripuana

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Together with influenza, the non-influenza RNA respiratory viruses (NIRVs), which include respiratory syncytial virus, parainfluenza viruses, coronavirus, rhinovirus, and human metapneumovirus, represent a considerable global health burden, as recognised by WHO's Battle against Respiratory Viruses initiative. By contrast with influenza viruses, little is known about the contemporaneous global diversity of these viruses, and the relevance of such for development of pharmaceutical interventions. Although far less advanced than for influenza, antiviral drugs and vaccines are in different stages of development for several of these viruses, but no interventions have been licensed. This scarcity of global genetic data represents a substantial knowledge gap and impediment to the eventual licensing of new antiviral drugs and vaccines for NIRVs. Enhanced genetic surveillance will assist and boost research and development into new antiviral drugs and vaccines for these viruses. Additionally, understanding the global diversity of respiratory viruses is also part of emerging disease preparedness, because non-human coronaviruses and paramyxoviruses have been listed as priority concerns in a recent WHO research and development blueprint initiative for emerging infectious diseases. In this Personal View, we explain further the rationale for expanding the genetic database of NIRVs and emphasise the need for greater investment in this area of research.

AB - Together with influenza, the non-influenza RNA respiratory viruses (NIRVs), which include respiratory syncytial virus, parainfluenza viruses, coronavirus, rhinovirus, and human metapneumovirus, represent a considerable global health burden, as recognised by WHO's Battle against Respiratory Viruses initiative. By contrast with influenza viruses, little is known about the contemporaneous global diversity of these viruses, and the relevance of such for development of pharmaceutical interventions. Although far less advanced than for influenza, antiviral drugs and vaccines are in different stages of development for several of these viruses, but no interventions have been licensed. This scarcity of global genetic data represents a substantial knowledge gap and impediment to the eventual licensing of new antiviral drugs and vaccines for NIRVs. Enhanced genetic surveillance will assist and boost research and development into new antiviral drugs and vaccines for these viruses. Additionally, understanding the global diversity of respiratory viruses is also part of emerging disease preparedness, because non-human coronaviruses and paramyxoviruses have been listed as priority concerns in a recent WHO research and development blueprint initiative for emerging infectious diseases. In this Personal View, we explain further the rationale for expanding the genetic database of NIRVs and emphasise the need for greater investment in this area of research.

UR - http://www.scopus.com/inward/record.url?scp=85018186741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018186741&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(17)30238-4

DO - 10.1016/S1473-3099(17)30238-4

M3 - Review article

C2 - 28457597

AN - SCOPUS:85018186741

VL - 17

SP - e320-e326

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

SN - 1473-3099

IS - 10

ER -